Beijing Wantai Biological Pharmacy Enterprise (SHA:603392) launched the phase III clinical trial of the lyophilized live attenuated varicella vaccine (VZV-7D), according to a Shanghai bourse disclosure on Friday.
The Chinese pharmaceutical company enrolled the first subject for the study of the vaccine, which helps boost the immune system against the varicella-zoster virus.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.